The stock has a 36-month beta value of 0.88. Opinions on the stock are mixed, with 3 analysts rating it as a “buy,” 1 as “overweight,” 17 as “hold,” and 5 as “sell.”
The public float for TEVA is 1.13B, and at present, short sellers hold a 2.68% of that float. On September 30, 2024, the average trading volume of TEVA was 8.57M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
TEVA) stock’s latest price update
The stock price of Teva- Pharmaceutical Industries Ltd. ADR (NYSE: TEVA) has dropped by -1.58 compared to previous close of 17.74. Despite this, the company has seen a fall of -0.29% in its stock price over the last five trading days. businesswire.com reported 2024-09-23 that MONTPELLIER, France–(BUSINESS WIRE)–New data presented by Teva at ECNP 2024* demonstrate switching to UZEDY at four weeks after the last dose of once-monthly Perseris® (RBP-7000) provided the most comparable pharmacokinetic (PK) profile based on relevant simulations, with comparable doses identified. Perseris manufacturer announced in July 2024 the discontinuation of its commercialization. Teva already presented in June 2024 data informing clinical strategies for switching patients to UZEDY f.
TEVA’s Market Performance
TEVA’s stock has fallen by -0.29% in the past week, with a monthly drop of -5.93% and a quarterly rise of 7.45%. The volatility ratio for the week is 1.94% while the volatility levels for the last 30 days are 2.49% for Teva- Pharmaceutical Industries Ltd. ADR The simple moving average for the last 20 days is -3.27% for TEVA’s stock, with a simple moving average of 17.67% for the last 200 days.
Analysts’ Opinion of TEVA
Many brokerage firms have already submitted their reports for TEVA stocks, with Argus repeating the rating for TEVA by listing it as a “Buy.” The predicted price for TEVA in the upcoming period, according to Argus is $20 based on the research report published on July 10, 2024 of the current year 2024.
JP Morgan, on the other hand, stated in their research note that they expect to see TEVA reach a price target of $14. The rating they have provided for TEVA stocks is “Neutral” according to the report published on March 08th, 2024.
Piper Sandler gave a rating of “Overweight” to TEVA, setting the target price at $19 in the report published on February 12th of the current year.
TEVA Trading at -1.34% from the 50-Day Moving Average
After a stumble in the market that brought TEVA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -8.49% of loss for the given period.
Volatility was left at 2.49%, however, over the last 30 days, the volatility rate increased by 1.94%, as shares sank -6.78% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +6.85% upper at present.
During the last 5 trading sessions, TEVA fell by -0.29%, which changed the moving average for the period of 200-days by +84.76% in comparison to the 20-day moving average, which settled at $17.99. In addition, Teva- Pharmaceutical Industries Ltd. ADR saw 67.24% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TEVA starting from Daniell Richard, who sale 98,943 shares at the price of $17.30 back on Aug 12 ’24. After this action, Daniell Richard now owns 0 shares of Teva- Pharmaceutical Industries Ltd. ADR, valued at $1,711,447 using the latest closing price.
Grant Angus, the EVP, Business Development of Teva- Pharmaceutical Industries Ltd. ADR, sale 4,065 shares at $17.28 during a trade that took place back on Aug 09 ’24, which means that Grant Angus is holding 8,848 shares at $70,243 based on the most recent closing price.
Stock Fundamentals for TEVA
Current profitability levels for the company are sitting at:
- 0.16 for the present operating margin
- 0.5 for the gross margin
The net margin for Teva- Pharmaceutical Industries Ltd. ADR stands at -0.03. The total capital return value is set at 0.09. Equity return is now at value -6.61, with -1.05 for asset returns.
Based on Teva- Pharmaceutical Industries Ltd. ADR (TEVA), the company’s capital structure generated 0.75 points at debt to capital in total, while cash flow to debt ratio is standing at 0.1. The debt to equity ratio resting at 2.93. The interest coverage ratio of the stock is 2.57.
Currently, EBITDA for the company is 4.27 billion with net debt to EBITDA at 3.71. When we switch over and look at the enterprise to sales, we see a ratio of 2.24. The receivables turnover for the company is 4.33for trailing twelve months and the total asset turnover is 0.39. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.89.
Conclusion
To sum up, Teva- Pharmaceutical Industries Ltd. ADR (TEVA) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “sell” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
